Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP558796.RAvMEyn_r-UIzGA1kaxKkzkt5HZNa-y2yuhDHB8ocQjeo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP558796.RAvMEyn_r-UIzGA1kaxKkzkt5HZNa-y2yuhDHB8ocQjeo130_assertion type Assertion NP558796.RAvMEyn_r-UIzGA1kaxKkzkt5HZNa-y2yuhDHB8ocQjeo130_head.
- NP558796.RAvMEyn_r-UIzGA1kaxKkzkt5HZNa-y2yuhDHB8ocQjeo130_assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP558796.RAvMEyn_r-UIzGA1kaxKkzkt5HZNa-y2yuhDHB8ocQjeo130_provenance.
- NP558796.RAvMEyn_r-UIzGA1kaxKkzkt5HZNa-y2yuhDHB8ocQjeo130_assertion evidence source_evidence_literature NP558796.RAvMEyn_r-UIzGA1kaxKkzkt5HZNa-y2yuhDHB8ocQjeo130_provenance.
- NP558796.RAvMEyn_r-UIzGA1kaxKkzkt5HZNa-y2yuhDHB8ocQjeo130_assertion SIO_000772 9767613 NP558796.RAvMEyn_r-UIzGA1kaxKkzkt5HZNa-y2yuhDHB8ocQjeo130_provenance.
- NP558796.RAvMEyn_r-UIzGA1kaxKkzkt5HZNa-y2yuhDHB8ocQjeo130_assertion wasDerivedFrom befree-20150227 NP558796.RAvMEyn_r-UIzGA1kaxKkzkt5HZNa-y2yuhDHB8ocQjeo130_provenance.
- NP558796.RAvMEyn_r-UIzGA1kaxKkzkt5HZNa-y2yuhDHB8ocQjeo130_assertion wasGeneratedBy ECO_0000203 NP558796.RAvMEyn_r-UIzGA1kaxKkzkt5HZNa-y2yuhDHB8ocQjeo130_provenance.